KR101365854B1 - Gpr119 효능제 - Google Patents

Gpr119 효능제 Download PDF

Info

Publication number
KR101365854B1
KR101365854B1 KR1020127000996A KR20127000996A KR101365854B1 KR 101365854 B1 KR101365854 B1 KR 101365854B1 KR 1020127000996 A KR1020127000996 A KR 1020127000996A KR 20127000996 A KR20127000996 A KR 20127000996A KR 101365854 B1 KR101365854 B1 KR 101365854B1
Authority
KR
South Korea
Prior art keywords
mmol
compound
methanesulfonyl
added
mixture
Prior art date
Application number
KR1020127000996A
Other languages
English (en)
Korean (ko)
Other versions
KR20120024964A (ko
Inventor
데이빗 진 바레트
아나 벨렌 부에노 멜렌도
제프리 버나드 프란시스코비치
빈 루
쿠미코 다케우치
Original Assignee
일라이 릴리 앤드 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43449712&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101365854(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 일라이 릴리 앤드 캄파니 filed Critical 일라이 릴리 앤드 캄파니
Publication of KR20120024964A publication Critical patent/KR20120024964A/ko
Application granted granted Critical
Publication of KR101365854B1 publication Critical patent/KR101365854B1/ko

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
KR1020127000996A 2009-07-15 2010-07-12 Gpr119 효능제 KR101365854B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP09382114 2009-07-15
EP09382114.8 2009-07-15
US24544509P 2009-09-24 2009-09-24
US61/245,445 2009-09-24
PCT/US2010/041645 WO2011008663A1 (en) 2009-07-15 2010-07-12 Gpr119 agonists

Publications (2)

Publication Number Publication Date
KR20120024964A KR20120024964A (ko) 2012-03-14
KR101365854B1 true KR101365854B1 (ko) 2014-02-21

Family

ID=43449712

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020127000996A KR101365854B1 (ko) 2009-07-15 2010-07-12 Gpr119 효능제

Country Status (24)

Country Link
US (1) US8207344B2 (US07794700-20100914-C00152.png)
EP (1) EP2454251A1 (US07794700-20100914-C00152.png)
JP (1) JP5715127B2 (US07794700-20100914-C00152.png)
KR (1) KR101365854B1 (US07794700-20100914-C00152.png)
CN (1) CN102471313B (US07794700-20100914-C00152.png)
AR (1) AR077638A1 (US07794700-20100914-C00152.png)
AU (1) AU2010273642B2 (US07794700-20100914-C00152.png)
BR (1) BRPI1015921A2 (US07794700-20100914-C00152.png)
CA (1) CA2764906C (US07794700-20100914-C00152.png)
CO (1) CO6480977A2 (US07794700-20100914-C00152.png)
CR (1) CR20120012A (US07794700-20100914-C00152.png)
DO (1) DOP2012000006A (US07794700-20100914-C00152.png)
EA (1) EA020540B1 (US07794700-20100914-C00152.png)
EC (1) ECSP12011606A (US07794700-20100914-C00152.png)
IL (1) IL216776A0 (US07794700-20100914-C00152.png)
MA (1) MA33428B1 (US07794700-20100914-C00152.png)
MX (1) MX2012000704A (US07794700-20100914-C00152.png)
NZ (1) NZ597125A (US07794700-20100914-C00152.png)
PE (1) PE20121045A1 (US07794700-20100914-C00152.png)
SG (1) SG177646A1 (US07794700-20100914-C00152.png)
TN (1) TN2012000002A1 (US07794700-20100914-C00152.png)
TW (1) TWI429634B (US07794700-20100914-C00152.png)
WO (1) WO2011008663A1 (US07794700-20100914-C00152.png)
ZA (1) ZA201200227B (US07794700-20100914-C00152.png)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ540612A (en) 2003-01-14 2008-02-29 Arena Pharm Inc 1,2,3-Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
EP2108960A1 (en) 2008-04-07 2009-10-14 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditons modulated by PYY
EP2547339A1 (en) 2010-03-18 2013-01-23 Boehringer Ingelheim International GmbH Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions
EP2619198A1 (en) 2010-09-22 2013-07-31 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012135570A1 (en) * 2011-04-01 2012-10-04 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
AU2012240122B2 (en) 2011-04-08 2016-08-25 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment
WO2012170702A1 (en) * 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
JP6463631B2 (ja) 2011-06-09 2019-02-06 ライゼン・ファーマシューティカルズ・エスアー Gpr−119のモジュレータとしての新規化合物
WO2012173917A1 (en) 2011-06-16 2012-12-20 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds, compositions containing such compounds, and methods of treatment
WO2013048916A1 (en) * 2011-09-30 2013-04-04 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment
US9018200B2 (en) 2011-10-24 2015-04-28 Merck Sharp & Dohme Corp. Substituted piperidinyl compounds useful as GPR119 agonists
WO2013062835A1 (en) * 2011-10-24 2013-05-02 Merck Sharp & Dohme Corp. Substituted piperidinyl compounds useful as gpr119 agonists
EP2780337B1 (en) 2011-11-15 2017-12-20 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds useful as gpr119 agonists
PT2858986T (pt) * 2012-06-12 2019-11-29 Chong Kun Dang Pharmaceutical Corp Derivados de piperidina como agonistas de gpr119
CN104780915A (zh) 2012-07-11 2015-07-15 埃尔舍利克斯治疗公司 包含他汀、双胍和用于减小心脏代谢风险的其它药剂的组合物
WO2014052619A1 (en) * 2012-09-27 2014-04-03 Irm Llc Piperidine derivatives and compositions as modulators of gpr119 activity
DK3074384T3 (da) * 2013-11-26 2019-07-15 Chong Kun Dang Pharmaceutical Corp Amidderivater til gpr119-agonist
KR101651505B1 (ko) * 2014-05-02 2016-08-29 현대약품 주식회사 싸이클로 헥센 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 대사성 질환의 예방 또는 치료용 약학적 조성물
EP4445956A2 (en) 2015-01-06 2024-10-16 Arena Pharmaceuticals, Inc. Compound for use in treating conditions related to the s1p1 receptor
WO2016209809A1 (en) 2015-06-22 2016-12-29 Arena Pharmaceuticals, Inc. Crystalline l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid(compound1) for use in sipi receptor-associated disorders
WO2018151873A1 (en) 2017-02-16 2018-08-23 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of primary biliary cholangitis
CA3178994A1 (en) 2020-05-19 2021-11-25 Iyassu Sebhat Ampk activators
AU2021297323A1 (en) 2020-06-26 2023-02-16 Kallyope, Inc. AMPK activators

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009038974A1 (en) * 2007-09-20 2009-03-26 Irm Llc Compounds and compositions as modulators of gpr119 activity

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ540612A (en) * 2003-01-14 2008-02-29 Arena Pharm Inc 1,2,3-Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
AU2007291252A1 (en) * 2006-08-30 2008-03-06 Inovacia Ab Pyridine compounds for treating GPR119 related disorders
US7638541B2 (en) * 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009038974A1 (en) * 2007-09-20 2009-03-26 Irm Llc Compounds and compositions as modulators of gpr119 activity

Also Published As

Publication number Publication date
JP5715127B2 (ja) 2015-05-07
PE20121045A1 (es) 2012-08-09
AU2010273642B2 (en) 2014-03-13
JP2012533546A (ja) 2012-12-27
CA2764906C (en) 2014-06-10
IL216776A0 (en) 2012-03-01
AR077638A1 (es) 2011-09-14
NZ597125A (en) 2013-08-30
DOP2012000006A (es) 2012-01-31
TN2012000002A1 (en) 2013-09-19
CN102471313B (zh) 2014-06-04
ZA201200227B (en) 2013-06-26
TWI429634B (zh) 2014-03-11
US8207344B2 (en) 2012-06-26
WO2011008663A1 (en) 2011-01-20
EA020540B1 (ru) 2014-11-28
CO6480977A2 (es) 2012-07-16
US20110015199A1 (en) 2011-01-20
ECSP12011606A (es) 2012-02-29
AU2010273642A1 (en) 2012-01-19
EP2454251A1 (en) 2012-05-23
KR20120024964A (ko) 2012-03-14
EA201270169A1 (ru) 2012-06-29
MA33428B1 (fr) 2012-07-03
SG177646A1 (en) 2012-02-28
CA2764906A1 (en) 2011-01-20
CR20120012A (es) 2012-03-28
TW201114757A (en) 2011-05-01
MX2012000704A (es) 2012-03-07
BRPI1015921A2 (pt) 2016-04-26
CN102471313A (zh) 2012-05-23

Similar Documents

Publication Publication Date Title
KR101365854B1 (ko) Gpr119 효능제
AU2006211583C1 (en) Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
AU2013227139B2 (en) Nitrogen-containing aromatic heterocyclic compound
WO2008025800A1 (en) Pyrimidine compounds for treating gpr119 related disorders
EP1716135B1 (en) Piperidinylcarbonyl-pyrrolidines and their use as melanocortin agonists
TW201835072A (zh) 新穎cyp11a1抑制劑
EP3781563B1 (en) Hpk1 inhibitors, preparation method and application thereof
KR20120130104A (ko) Gpr119 작동약
WO2009150144A1 (en) New gpr119modulators
JPWO2010013849A1 (ja) Gpr119作動薬
KR101665749B1 (ko) 5-하이드록시피리미딘-4-카르복사미드 유도체
KR20110133045A (ko) 대사성 장애의 치료용 화합물
JP2014094886A (ja) Gpr119作動薬
TW202136271A (zh) 呋喃并吲唑衍生物
WO2013062835A1 (en) Substituted piperidinyl compounds useful as gpr119 agonists
WO2012006955A1 (en) Compounds for treatment of metabolic disorders
KR101372743B1 (ko) Nk3 수용체 길항제로서 피페리딘 유도체
JP2013047188A (ja) Gpr119作動薬
EP3212638B1 (en) New dihydroquinoline pyrazolyl compounds as aldosterone synthase inhibitors
CN116102543A (zh) 一种glp-1r激动剂、合成方法及其用途

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
LAPS Lapse due to unpaid annual fee